Overview

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

Status:
Completed
Trial end date:
2021-04-14
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, multi-center study of BGB-290 administered orally (PO) twice daily (BID) in adult Chinese patients with advanced HER2(-) breast cancer harboring germline BRCA mutation, which have progressed despite standard therapy, or for which no standard therapy exists.
Phase:
Phase 2
Details
Lead Sponsor:
BeiGene